These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32584374)

  • 21. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.
    Sturdivant JM; Royalty SM; Lin CW; Moore LA; Yingling JD; Laethem CL; Sherman B; Heintzelman GR; Kopczynski CC; deLong MA
    Bioorg Med Chem Lett; 2016 May; 26(10):2475-2480. PubMed ID: 27072905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rhopressa-induced corneal edema: a case report.
    Chu MJ; Song M; Palmares T; Song A; Song J
    J Med Case Rep; 2021 Apr; 15(1):182. PubMed ID: 33810801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symptomatic Netarsudil-Induced Verticillata.
    Rivera SS; Radunzel N; Boese EA
    JAMA Ophthalmol; 2023 Nov; 141(11):e232949. PubMed ID: 37971506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corneal oedema and acute anterior uveitis after two doses of travoprost.
    Aydin S; Ozcura F
    Acta Ophthalmol Scand; 2007 Sep; 85(6):693-4. PubMed ID: 17403018
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in medical therapy for glaucoma.
    Ostler E; Rhee D; Burney E; Sozeri Y
    Curr Opin Ophthalmol; 2021 Mar; 32(2):129-133. PubMed ID: 33395110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consultation section. Cataract surgical problem.
    J Cataract Refract Surg; 2009 Oct; 35(10):1836-43. PubMed ID: 19781485
    [No Abstract]   [Full Text] [Related]  

  • 27. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
    Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
    Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial.
    Garcia-Medina JJ; Garcia-Medina M; Garrido-Fernandez P; Galvan-Espinosa J; Garcia-Maturana C; Zanon-Moreno V; Pinazo-Duran MD
    Acta Ophthalmol; 2015 Sep; 93(6):546-54. PubMed ID: 25545196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ripasudil on diabetic macular edema.
    Minami Y; Song YS; Ishibazawa A; Omae T; Ro-Mase T; Ishiko S; Yoshida A
    Sci Rep; 2019 Mar; 9(1):3703. PubMed ID: 30842496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
    Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Series: Novel Utilization of Rho-Kinase Inhibitor for the Treatment of Corneal Edema.
    Davies E
    Cornea; 2021 Jan; 40(1):116-120. PubMed ID: 33269892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anterior-Segment Optical Coherence Tomography and Scanning Electron Microscopy to Evaluate Corneal Epithelial Changes in Patients Undergoing Glaucoma Therapy.
    Cennamo G; Montorio D; Del Prete S; Del Prete A; Cennamo G
    Cornea; 2018 Dec; 37(12):1522-1526. PubMed ID: 30212410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness.
    Schrems WA; Schrems-Hoesl LM; Mardin CY; Horn FK; Juenemann AG; Kruse FE; Braun JM; Laemmer R
    J Glaucoma; 2016 Mar; 25(3):274-80. PubMed ID: 25383467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional correlation of macular areas and visual acuity in patients with open-angle glaucoma.
    Omodaka K; Yabana T; Takada N; Nakazawa T
    Clin Exp Ophthalmol; 2015 Apr; 43(3):279-82. PubMed ID: 25078071
    [No Abstract]   [Full Text] [Related]  

  • 35. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
    Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
    Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in visual function after intraocular pressure reduction using antiglaucoma medications.
    Prata TS; Piassi MV; Melo LA
    Eye (Lond); 2009 May; 23(5):1081-5. PubMed ID: 18670465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier.
    Furuichi M; Chiba T; Abe K; Kogure S; Iijima H; Tsukahara S; Kashiwagi K
    J Glaucoma; 2001 Jun; 10(3):233-6. PubMed ID: 11442189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Near-term analysis of corneal epithelial thickness after cataract surgery and its correlation with epithelial cell changes and visual acuity.
    Zheng T; Yang J; Xu J; He W; Lu Y
    J Cataract Refract Surg; 2016 Mar; 42(3):420-6. PubMed ID: 27063523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect.
    Kobayashi H; Kobayashi K
    J Glaucoma; 2011 Jan; 20(1):3-6. PubMed ID: 20520573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil.
    Jeang LJ; Shah AS; Hammer JD; Tuli SS
    Digit J Ophthalmol; 2022; 28(8):34-37. PubMed ID: 35854963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.